Diane Pang


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Diane Pang, Ph.D., is an accomplished lawyer specializing in intellectual property and technology and life sciences matters. In addition to her law degree, Diane holds a doctorate in pharmaceutical chemistry, which helps her counsel pharmaceutical and biotechnology clients in the acquisition and protection of their intellectual property rights, particularly in the prosecution and enforcement of patents.

Diane has specific experience in the development of patent portfolios for biotechnology and healthcare-related companies, including the preparation and prosecution of patent applications relating to the pharmaceutical, chemical, biotechnology and medical device sectors. Additionally, she has significant experience with intellectual property litigation and transactional matters, such as licensing and technology transfer agreements, due diligence analysis of intellectual property rights, and trademark clearance and prosecution.


Bar Admissions

  • California

Court Admissions

  • US District Court, Central District of California

Registered to Practice

  • US Patent & Trademark Office


  • University of California at Berkeley, J.D.
  • University of California at San Francisco, Ph.D., Pharmaceutical Chemistry
  • California Institute of Technology, B.S., Chemistry: with honors 

Professional Activities


  • “Supreme Court Back in the Patent Limelight,” Orange County Business Journal (August 2014)
  • Genetics Institute, LLC v. Novartis Vaccines And Diagnostics, Inc. After bench trial to Judge Robinson in Delaware, secured a ruling of no invalidity of Novartis's patents directed to synthetic, recombinant blood coagulation protein Factor VIII used in treatment of Hemophilia A. Genetics Institute, LLC v. Novartis Vaccines and Diagnostics, Inc., 687 F. Supp. 2d 486 (2010).  The Federal Circuit upheld that ruling in a majority 2-1 precedential opinion. Genetics Institute, LLC v. Novartis Vaccines and Diagnostics, Inc., 655 F.3d 1291 (Fed. Cir. 2011), and the US Supreme Court denied certiorari, which resulted in a favorable resolution of underlying infringement litigation.
  • Novartis Vaccines and Diagnostics, Inc. et al. v. Medimmune, LLC, Biogen IDEC, Inc., and Alexion Pharmaceuticals, Inc. (DED Civil Action No. 11-CV-84-SLR-MPT). Enforced a Novartis patent directed to cytomegalovirus expression systems and their use in manufacturing of biologics.  All three actions filed against the manufacturers of biologics Synagis, Tysabri, and Soliris were successfully resolved.
  • Affymetrix, Inc. v. Multilyte Ltd. (N.D. Ca. Civil Action No. C-03-0379 WHA).  Represented Affymetrix in declaratory judgment patent infringement action against Multilyte involving DNA microarray devices for RNA expression analysis.  Obtained summary judgment of no liability in favor of Affymetrix.
  • Vicuron Pharmaceuticals Inc.  Represented Vicuron Pharmaceuticals, a company developing anti-infectives for hospital-based and community acquired MRSA infections, in its $1.9 billion acquisition by Pfizer Inc.